Table 3.
Score | Region of interest | Coefficient | pval | 95% Confidence Interval |
---|---|---|---|---|
MDS-UPDRS III | PUT* | −9.2 | 0.022 | [− 17; − 1.4] |
CN* | −4.4 | 0.44 | [− 15.6; 6.8] | |
PAL* | −1.46 | 0.67 | [−8.1; 5.2] | |
INS | − 3.4 | 0.22 | [−8.9; 2.0] | |
AMYG | −1.8 | 0.25 | [−4.8; 1.2] | |
MOCA | PUT | −0.47 | 0.62 | [−2.3; 1.4] |
CN | −0.26 | 0.74 | [−1.8; 1.3] | |
PAL | −0.1 | 0.85 | [−1.2; 1] | |
INS | −0.02 | 0.97 | [−1.3; 1.2] | |
AMYG | −0.26 | 0.46 | [−1; 0.4] | |
GDS | PUT | 0.54 | 0.39 | [−0.7; 1.8] |
CN | −0.30 | 0.56 | [−1.3; 0.7] | |
PAL | −0.65 | 0.08 | [−1.4; 0.1] | |
INS | 0.51 | 0.22 | [−0.3; 1.3] | |
AMYG | −0.13 | 0.59 | [−0.6; 1.3] | |
SCOPA-GI | PUT | −2.2 | 0.01 | [−3.9; −0.5] |
CN | −1.48 | 0.034 | [−2.9; −0.1] | |
PAL | −0.06 | 0.90 | [−1.1; 1] | |
INS | −0.66 | 0.25 | [−1.8; 0.5] | |
AMYG | −0.2 | 0.54 | [−0.8; 0.4] | |
SCOPA-URO | PUT | −2.7 | 0.013 | [−4.6; −0.6] |
CN | −2.7 | 0.002 | [−4.3; −1.0] | |
PAL | −1.4 | 0.025 | [−2.7; −0.2] | |
INS | −0.66 | 0.36 | [−2.1; 0.75] | |
AMYG | −0.44 | 0.27 | [−1.2; 0.4] | |
ESS | PUT | −0.79 | 0.63 | [−4; 2.4] |
CN | −0.33 | 0.81 | [−3.1; 2.4] | |
PAL | −0.99 | 0.30 | [−2.9; 0.9] | |
INS | 0.25 | 0.81 | [−1.8; 2.3] | |
AMYG | 0.01 | 0.99 | [−1.1; 1.1] | |
RBDSQ | PUT | −3.27 | 0.010 | [−5.7; −0.8] |
CN | −2.35 | 0.028 | [−4.4; − 0.3] | |
PAL | −1.56 | 0.036 | [−3.0; −0.1] | |
INS | −0.08 | 0.92 | [−1.7; 1.54] | |
AMYG | 0.37 | 0.40 | [−0.52; 1.27] |
Correlations between clinical scores and 123I-FP-CIT ROIs uptake. All uptake values are average (mean of left and right), except * = contralateral side to clinically more affected side. PUT putamen, CN caudate nucleus, PAL pallidum, INS insula, AMYG amygdala. Significant results are highlighted in bold